Luminex, HTG launch qBead Gene Expression Assay

Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA™), today launched a new custom gene expression product, the qBead Gene Expression Assay (qBead Assay). The companies co-developed the product and have signed an exclusive distribution agreement in which Luminex will begin offering it to the research community.

"Advances in discovery through sequencing and high-density arrays have driven significant growth in the mid-plex custom gene expression research market," said TJ Johnson, CEO of HTG. "Scientists in this area validate gene expression signatures and screen established panels.  They often need custom assays that allow them to quickly and accurately measure a select set of genes in many samples. With the qBead Assay, HTG and Luminex have joined forces to meet this need."

The new qBead Assay places HTG's proven qNPA™ chemistry on the Luminex xMAP® Technology multiplexing platform.  The result is a high-throughput assay with a simplified workflow that requires no extractions, cDNA synthesis or amplifications.  The qBead assay is uniquely suited for scientists who need to get high quality gene expression data from degraded samples or difficult samples such as Formalin-Fixed Paraffin-Embedded (FFPE) and other fixed tissues where RNA quality is an issue.

Researchers can order a qBead Assay that is custom-tailored to their genes of interest and optimized for their sample type.

"The combination of xMAP Technology from Luminex and the qBead Assay represents an advance for many scientists, including cancer researchers who perform retrospective studies on large numbers of archived samples," said Patrick J. Balthrop, president and CEO of Luminex.  "Luminex is excited to partner with HTG to leverage our scientific and technical expertise and respective technologies to create high-throughput, custom assays that will advance the work of researchers in the critical, growing mid-plex custom gene expression research arena."

Custom qBead Assays employ Luminex's MagPlex® magnetic beads.  They allow multiplexed measurement of multiple gene expression signatures per sample that have the opportunity to run on the thousands of Luminex 100/200™ instruments installed, and can utilize the high-throughput, 500-gene multiplexing capability of the new Luminex FLEXMAP 3D® instrument.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Luminex. (2019, June 17). Luminex, HTG launch qBead Gene Expression Assay. News-Medical. Retrieved on April 24, 2024 from

  • MLA

    Luminex. "Luminex, HTG launch qBead Gene Expression Assay". News-Medical. 24 April 2024. <>.

  • Chicago

    Luminex. "Luminex, HTG launch qBead Gene Expression Assay". News-Medical. (accessed April 24, 2024).

  • Harvard

    Luminex. 2019. Luminex, HTG launch qBead Gene Expression Assay. News-Medical, viewed 24 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins